Systematic investigation of genetically determined plasma and urinary metabolites to discover potential interventional targets for colorectal cancer.
Loading...
Embargo End Date
ICR Authors
Authors
Sun, J
Zhao, J
Zhou, S
Li, X
Li, T
Wang, L
Yuan, S
Chen, D
Law, PJ
Larsson, SC
Farrington, SM
Houlston, RS
Dunlop, MG
Theodoratou, E
Li, X
Zhao, J
Zhou, S
Li, X
Li, T
Wang, L
Yuan, S
Chen, D
Law, PJ
Larsson, SC
Farrington, SM
Houlston, RS
Dunlop, MG
Theodoratou, E
Li, X
Document Type
Journal Article
Date
2024-08-01
Date Accepted
2024-04-13
Abstract
BACKGROUND: We aimed to identify plasma and urinary metabolites related to colorectal cancer (CRC) risk and elucidate their mediator role in the associations between modifiable risk factors and CRC. METHODS: Metabolite quantitative trait loci were derived from 2 published metabolomics genome-wide association studies, and summary-level data were extracted for 651 plasma metabolites and 208 urinary metabolites. Genetic associations with CRC were obtained from a large-scale genome-wide association study meta-analysis (100 204 cases, 154 587 controls) and the FinnGen cohort (4957 cases, 304 197 controls). Mendelian randomization and colocalization analyses were performed to evaluate the causal roles of metabolites in CRC. Druggability evaluation was employed to prioritize potential therapeutic targets. Multivariable Mendelian randomization and mediation estimation were conducted to elucidate the mediating effects of metabolites on the associations between modifiable risk factors and CRC. RESULTS: The study identified 30 plasma metabolites and 4 urinary metabolites for CRC. Plasma sphingomyelin and urinary lactose, which were positively associated with CRC risk, could be modulated by drug interventions (ie, olipudase alfa, tilactase). Thirteen modifiable risk factors were associated with 9 metabolites, and 8 of these modifiable risk factors were associated with CRC risk. These 9 metabolites mediated the effect of modifiable risk factors (Actinobacteria, body mass index, waist to hip ratio, fasting insulin, smoking initiation) on CRC. CONCLUSION: This study identified key metabolite biomarkers associated with CRC and elucidated their mediator roles in the associations between modifiable risk factors and CRC. These findings provide new insights into the etiology and potential therapeutic targets for CRC and the etiological pathways of modifiable environmental factors with CRC.
Citation
Journal of the National Cancer Institute, 2024, 116 (8), pp. 1303 - 1312
Source Title
Journal of the National Cancer Institute
Publisher
OXFORD UNIV PRESS INC
ISSN
0027-8874
eISSN
1460-2105
Collections
Research Team
Cancer Genomics